This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PreAsthmaControl (PAC)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 5, 2005
Last updated: January 21, 2011
Last verified: January 2011
The purpose of this study is to investigate the ability of budesonide, given during episodes of troublesome lung symptoms to reduce further symptoms in infants and young children at risk of developing asthma

Condition Intervention Phase
Asthma Drug: Pulmicort (budesonide) pMDI Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Prevention of Asthma in Infants/Young Children - PAC

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • symptom free days
  • days with no use of bronchodilator
  • days with no use of bronchodilator and no symptoms
  • number of treated episodes
  • number of treatment with add-on medication

Secondary Outcome Measures:
  • asthma status
  • time to start of algorithm treatment
  • the total steroid dose
  • First treatment episode:
  • number of symptom days
  • number of days with use of bronchodilator
  • number of patients who needed add-on medication
  • BMD
  • height
  • serious adverse events

Estimated Enrollment: 400
Study Start Date: November 1998
Study Completion Date: December 2004

Ages Eligible for Study:   up to 6 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children of asthmatic mothers form the COPSAC birth cohort study

Exclusion Criteria:

  • Children born more than 4 weeks preterm
  • children with other systemic illness that atopy/allergy
  • Children requiring mechanical ventilation at any time since birth.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00234390

Research Site
Copenhagen, Denmark
Sponsors and Collaborators
Study Director: AstraZeneca AB CNS Medical Science Director, MD AstraZeneca
  More Information

Publications: Identifier: NCT00234390     History of Changes
Other Study ID Numbers: SD-004-0299
Study First Received: October 5, 2005
Last Updated: January 21, 2011

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on September 21, 2017